2月27日 - ** 药物开发商Aardvark Therapeutics AARD.O股价盘后下跌47.2%至6.58美元
** 该公司表示，它将自愿暂停 (link) 其晚期试验，测试其治疗一种罕见遗传病的实验性疗法。
** 该公司称，在对接受超计划剂量治疗的健康志愿者进行安全监测时，发现了与心脏有关的副作用，因此做出了这一决定。
** 表示不再预计在 2026 年第三季度公布试验的初步数据
** 自去年在纳斯达克上市以来，该公司股价已下跌12.6%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.